Mei-Tsen Chen1, Shih-Tsung Huang1, Chih-Wan Lin1, Bor-Sheng Ko2,3, Wen-Jone Chen4, Huai-Hsuan Huang2, Fei-Yuan Hsiao1,5,6. 1. Graduate Institute of Clinical Pharmacy, National Taiwan University, Taipei, Taiwan. 2. Division of Hematology, National Taiwan University Hospital, Taipei, Taiwan. 3. Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. 4. Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. 5. School of Pharmacy, National Taiwan University, Taipei, Taiwan. 6. Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan.
Abstract
BACKGROUND: Tyrosine kinase inhibitors (TKIs) have shown long-term survival benefits in patients with chronic myeloid leukemia (CML). Nevertheless, significant concern has been raised regarding long-term TKI-associated vascular adverse events (VAEs). The objective of this retrospective cohort study was to investigate the incidence of VAEs in Taiwanese patients with CML treated with different TKIs (imatinib, nilotinib, and dasatinib) as well as potential risk factors. MATERIALS AND METHODS: We conducted a retrospective cohort study using the Taiwan Cancer Registry Database and National Health Insurance Research Database. Adult patients diagnosed with CML from 2008 to 2016 were identified and categorized into three groups according to their first-line TKI treatment (imatinib, nilotinib, and dasatinib). Propensity score matching was performed to control for potential confounders. Cox regressions were used to estimate the hazard ratio (HR) of VAEs in different TKI groups. RESULTS: In total, 1,111 patients with CML were included in our study. We found that the risk of VAEs in nilotinib users was significantly higher than that in imatinib users, with an HR of 3.13 (95% confidence interval (CI), 1.30-7.51), whereas dasatinib users also showed a nonsignificant trend for developing VAEs, with an HR of 1.71 (95% CI, 0.71-4.26). In multivariable logistic regression analysis, only nilotinib usage, older age, and history of cerebrovascular diseases were identified as significant risk factors. The annual incidence rate of VAEs was highest within the first year after the initiation of TKIs. CONCLUSION: These findings can support clinicians in making treatment decisions and monitoring VAEs in patients with CML in Taiwan. IMPLICATIONS FOR PRACTICE: This study found that patients with chronic myeloid leukemia (CML) treated with nilotinib and dasatinib may be exposed to a higher risk of developing vascular adverse events (VAEs) compared with those treated with imatinib. Thus, this study suggests that patients with CML who are older or have a history of cerebrovascular diseases should be under close monitoring of VAEs, particularly within the first year after the initiation of tyrosine kinase inhibitors.
BACKGROUND: Tyrosine kinase inhibitors (TKIs) have shown long-term survival benefits in patients with chronic myeloid leukemia (CML). Nevertheless, significant concern has been raised regarding long-term TKI-associated vascular adverse events (VAEs). The objective of this retrospective cohort study was to investigate the incidence of VAEs in Taiwanese patients with CML treated with different TKIs (imatinib, nilotinib, and dasatinib) as well as potential risk factors. MATERIALS AND METHODS: We conducted a retrospective cohort study using the Taiwan Cancer Registry Database and National Health Insurance Research Database. Adult patients diagnosed with CML from 2008 to 2016 were identified and categorized into three groups according to their first-line TKI treatment (imatinib, nilotinib, and dasatinib). Propensity score matching was performed to control for potential confounders. Cox regressions were used to estimate the hazard ratio (HR) of VAEs in different TKI groups. RESULTS: In total, 1,111 patients with CML were included in our study. We found that the risk of VAEs in nilotinib users was significantly higher than that in imatinib users, with an HR of 3.13 (95% confidence interval (CI), 1.30-7.51), whereas dasatinib users also showed a nonsignificant trend for developing VAEs, with an HR of 1.71 (95% CI, 0.71-4.26). In multivariable logistic regression analysis, only nilotinib usage, older age, and history of cerebrovascular diseases were identified as significant risk factors. The annual incidence rate of VAEs was highest within the first year after the initiation of TKIs. CONCLUSION: These findings can support clinicians in making treatment decisions and monitoring VAEs in patients with CML in Taiwan. IMPLICATIONS FOR PRACTICE: This study found that patients with chronic myeloid leukemia (CML) treated with nilotinib and dasatinib may be exposed to a higher risk of developing vascular adverse events (VAEs) compared with those treated with imatinib. Thus, this study suggests that patients with CML who are older or have a history of cerebrovascular diseases should be under close monitoring of VAEs, particularly within the first year after the initiation of tyrosine kinase inhibitors.
Authors: Jeffrey H Lipton; Charles Chuah; Agnès Guerci-Bresler; Gianantonio Rosti; David Simpson; Sarit Assouline; Gabriel Etienne; Franck E Nicolini; Philipp le Coutre; Richard E Clark; Leif Stenke; David Andorsky; Vivian Oehler; Stephanie Lustgarten; Victor M Rivera; Timothy Clackson; Frank G Haluska; Michele Baccarani; Jorge E Cortes; François Guilhot; Andreas Hochhaus; Timothy Hughes; Hagop M Kantarjian; Neil P Shah; Moshe Talpaz; Michael W Deininger Journal: Lancet Oncol Date: 2016-04-12 Impact factor: 41.316
Authors: R A Larson; A Hochhaus; T P Hughes; R E Clark; G Etienne; D-W Kim; I W Flinn; M Kurokawa; B Moiraghi; R Yu; R E Blakesley; N J Gallagher; G Saglio; H M Kantarjian Journal: Leukemia Date: 2012-05-18 Impact factor: 11.528
Authors: Hagop M Kantarjian; Andreas Hochhaus; Giuseppe Saglio; Carmino De Souza; Ian W Flinn; Leif Stenke; Yeow-Tee Goh; Gianantonio Rosti; Hirohisa Nakamae; Neil J Gallagher; Albert Hoenekopp; Rick E Blakesley; Richard A Larson; Timothy P Hughes Journal: Lancet Oncol Date: 2011-08-17 Impact factor: 41.316
Authors: M Breccia; M Muscaritoli; F Gentilini; R Latagliata; I Carmosino; F Rossi Fanelli; G Alimena Journal: Leuk Res Date: 2007-03-26 Impact factor: 3.156